Jason Westin

Dr. Jason Westin, a professor at MD Anderson and ASCO board member, dives into challenges oncologists may face by 2026, including funding cuts for cancer research and ongoing drug shortages. He emphasizes the need for advocacy, presenting strategies for oncologists to make a difference. Westin discusses the risk of losing U.S. leadership in research due to declining federal investment and explores policy solutions to ensure reliable drug manufacturing. His insights aim to empower oncologists to take an active role in shaping the future of cancer care.

Dr. Jason Westin, a lymphoma expert at MD Anderson, and Dr. Surbhi Sidana, who leads Stanford's Myeloma CAR-T program, dive into the intricacies of CAR-T cell therapy. They discuss its powerful mechanism and its application in treating cancers. The conversation highlights acute side effects like cytokine release syndrome and neurotoxicity, alongside strategies for their management. Chronic side effects, including infection risks and monitoring practices, are also explored, providing vital insights for oncologists on patient care.

In this discussion, Stephen Schuster and Jason Westin from top cancer centers delve into the latest in CAR T-cell therapy for non-Hodgkin lymphoma. They explore the treatment landscape, strategies to manage toxicities, and the promise of allogeneic CAR-T products. Joining them, Stephen Ansell and Martin Hutchings share insights on the role of bispecific antibodies, comparing their efficacy against CAR T therapies. They also address unique challenges and exciting combinations with antibody-drug conjugates that could redefine treatment approaches.